个性化烟草治疗干预对符合肺癌筛查条件者戒烟效果的影响
该两阶段序贯随机对照试验纳入188例正在接受或符合肺癌筛查的患者,评估增益框架信息联合标准治疗能否提高8周生化验证戒烟率,以及烟草相关生物标志物反馈能否减少6个月每日吸烟支数。结果增益框架信息未显著改善戒烟率,生物标志物反馈未显著减少每日吸烟支数,但整体方案在该老年高包年队列中实现了有临床意义的戒烟率。
要点
- 标准治疗联合增益框架信息组8周戒烟率16.1%,标准治疗组16.8%,两组无显著差异(P=0.90)。
- 6个月随访时,反馈组每日吸烟支数最小二乘均值7.5(95%CI 6.0-9.1),无反馈组7.7(95%CI 6.2-9.3),两组相似(P=0.87)。
- 整体方案在老年高包年队列中实现了有临床意义的戒烟率,凸显强化烟草治疗对肺癌筛查患者的重要性。
核心结论
- 增益框架信息联合标准治疗未较全面标准治疗显著改善戒烟率,烟草相关生物标志物反馈未较无反馈显著减少6个月每日吸烟支数。
- 整体方案在老年高包年队列中实现了有临床意义的戒烟率,凸显强化烟草治疗对肺癌筛查患者的重要性。
研究设计与样本
- 两阶段序贯随机对照试验,2016年至2020年纳入188例正在接受或符合肺癌筛查的患者。
- 第一阶段评估标准治疗联合增益框架信息对比标准治疗对8周生化验证戒烟率的影响,标准治疗为5次面对面咨询和8周尼古丁贴片。
- 第二阶段143例随机分组,评估烟草相关生物标志物反馈对比无反馈对6个月自报每日吸烟支数的影响。
- 采用卡方检验和混合效应重复测量分析评估组间差异。
主要发现
- 参与者平均年龄62.5±5.6岁,平均吸烟史50.3±21包年,每日吸烟16.9±9.9支。
- 8周时,标准治疗联合增益框架信息组戒烟15/93例(16.1%),标准治疗组16/95例(16.8%),P=0.90,两组无差异。
- 6个月随访时,反馈组每日吸烟支数最小二乘均值7.5(95%CI 6.0-9.1),无反馈组7.7(95%CI 6.2-9.3),P=0.87,两组相似。
关键数值与推荐
- 标准治疗联合增益框架信息组8周生化验证戒烟率16.1%(15/93),标准治疗组16.8%(16/95),P=0.90。
- 反馈组6个月每日吸烟支数最小二乘均值7.5(95%CI 6.0-9.1),无反馈组7.7(95%CI 6.2-9.3),P=0.87。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To determine whether personalized gain-framed messaging and biomarker feedback related to tobacco cessation or reduction decrease smoking behavior in patients undergoing or eligible for lung cancer screening. METHODS: Between 2016 and 2020, 188 patients were enrolled in a two-phase, sequential, randomized controlled trial. Phase 1 evaluated whether standard of care (SC) (five in-person counseling sessions and 8 weeks of nicotine patch) plus gain-framed messaging (GFM) versus SC would increase 8-week biochemically verified smoking cessation rates. In 143 participants randomized in phase 2, we tested whether feedback on smoking-related biomarkers would reduce 6-month self-reported number of cigarettes smoked per day compared with a no feedback control. Chi-square test and mixed effects repeated measures analyses were used to evaluate group differences. RESULTS: Participants were 62.5 ± 5.6 (mean ± SD) years of age, had a 50.3 ± 21 pack-year smoking history, and were smoking 16.9 ± 9.9 cigarettes per day. At 8 weeks, there was no difference in quit rates between those randomized to SC plus GFM (n = 15 of 93, 16.1%) and those randomized to SC (n = 16 of 95, 16.8%), with p equals to 0.90. At the 6-month post-randomization follow-up, number of cigarettes smoked per day was similar in the feedback (least-squares mean = 7.5, 95% confidence interval: 6.0-9.1) and no feedback arms (7.7, 95% confidence interval: 6.2-9.3), with p equals to 0.87. CONCLUSIONS: Gain-framed messaging and health feedback did not significantly improve quit rates relative to comprehensive standard of care. Nevertheless, the overall program achieved clinically meaningful smoking quit rates in this older high pack-year cohort, highlighting the importance of intensive tobacco treatment for patients undergoing lung cancer screening. CLINICAL TRIAL REGISTERED WITH CLINICALTRIALS.GOV: NCT02658032.
引用
- Cartmel B, Fucito LM, Bold KW, et al. Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening. J Thorac Oncol. 2023. PMID: 37977486. doi:10.1016/j.jtho.2023.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。